Schizophrenia Research and Treatment

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia


Publishing date
10 Aug 2012
Status
Published
Submission deadline
30 Mar 2012

1Clinic Schizophrenia Program (PEC), Department of Psychiatry, Hospital Clínic of Barcelona, University of Barcelona, Catalonia, Spain

2Department of Psychiatry, University of Texas Health Science Center San Antonio, 7300 Floyd Curl Drive, San Antonio, TX 78229, USA

3Department of Psychiatry, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, Cape Town 7500, South Africa

4Klinik und Poliklinic für Psychiatrie und Psychotherapie, Klinikum Rechts der Isar Technische Universitaet Muenchen, Moehlstraße 26, 81675 Munich, German


Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia

Description

Long-acting injectable antipsychotics (LAIA) may improve adherence to treatment and reduce the rate of relapse and rehospitalization in first-episode or recent-onset schizophrenia (less than 2 years of illness duration). However, the place of LAIA in early phases of schizophrenia is still a controversial clinical issue. For example, negative attitudes toward LAIA in first-episode schizophrenia among psychiatrists are common; the place of LAIA for first-episode psychoses remains uncertain in the current clinical guidelines for the pharmacological treatment of schizophrenia. Moreover, a recent paper published in the New England Journal of Medicine (Rosenheck R et al., March 2011), showing negative results of LAI risperidone on relapse prevention, as well as the availability of the forthcoming second-generation LAIA (olanzapine pamoate, paliperidone palmitate, and aripiprazole depot), will add interest in this clinical debate.

We invite authors to submit original research and review articles that seek to define the place of LAIA in the treatment of first-episode or recent-onset schizophrenia. Potential topics include, but are not limited to:

  • LAIA randomized clinical trials or observational studies focusing on efficacy and tolerability in first-episode or recent-onset schizophrenia
  • Long-term studies comparing LAIA with oral medication after first-episode psychosis regarding relapse prevention
  • Altering disease trajectory: can LAIA improve long-term outcomes by reducing early relapse and loss of function in first-onset patients?
  • Psychiatrist attitudes to LAIA in first-episode schizophrenia
  • Patient preferences and attitudes to LAIA in early phases of the illness
  • Therapeutic alliance and ethics of LAIA in first-episode psychoses
  • Role of LAIA in relapse prevention strategies in first-episode schizophrenia
  • Nonadherence of LAIA in early phases of the schizophrenia
  • Cost-effectiveness studies comparing LAIA with oral antipsychotic treatments in first-episode schizophrenia patients

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/sprt/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2012
  • - Article ID 318535
  • - Editorial

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia

Eduard Parellada | Dawn I. Velligan | ... | Werner Kissling
  • Special Issue
  • - Volume 2012
  • - Article ID 560836
  • - Review Article

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons

Borah Kim | Sang-Hyuk Lee | ... | Young-Chul Chung
  • Special Issue
  • - Volume 2012
  • - Article ID 791468
  • - Clinical Study

Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection

Christian Asseburg | Michael Willis | ... | Ulf Persson
  • Special Issue
  • - Volume 2012
  • - Article ID 764769
  • - Review Article

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective

Radovan Přikryl | Hana Přikrylová Kučerová | ... | Eva Češková
  • Special Issue
  • - Volume 2012
  • - Article ID 368687
  • - Clinical Study

Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia

Annie Viala | Françoise Cornic | Marie-Noëlle Vacheron
  • Special Issue
  • - Volume 2012
  • - Article ID 407171
  • - Review Article

Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review

Simon Zhornitsky | Emmanuel Stip
Schizophrenia Research and Treatment
 Journal metrics
Acceptance rate-
Submission to final decision1 days
Acceptance to publication-
CiteScore2.710
Impact Factor-
 Submit